Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on November 9, 2016. The filing serves to incorporate by reference a news release and a sales agreement regarding the establishment of an At-the-Market (ATM) equity offering facility.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the corporate action of establishing an equity offering facility rather than reporting financial performance results.
Material Changes
The primary material change disclosed is the execution of a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. dated November 9, 2016. This agreement establishes an ATM facility allowing the company to sell shares of its common stock through Cantor Fitzgerald as agent.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The document is a procedural filing to disclose the ATM facility agreement and incorporate it into the company's Registration Statement on Form F-10 (File No. 333-206994).
Key Facts for Investor Verification
- The company has established an At-the-Market equity offering facility with Cantor Fitzgerald & Co.
- The agreement is dated November 9, 2016, and is incorporated into the Form F-10 registration statement.
- No financial performance data or operational metrics are included in this specific filing.
- The filing was signed by Dennis Bourgeault, Chief Financial Officer.